Novocol Pharmaceutical of Canada Inc.
$32,716,000.00 CAD
- Program
- SIF Stream 1- R&D
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- March 1, 2021 – December 31, 2023
- Reference
- ic:033-2020-2021-Q4-815860
Published purpose
This project will support the expansion of existing bio-manufacturing facilities and increasing fill-finish capacity for vaccines/therapies, including live and viral vector vaccines.
In plain English AI-generated
Funding supports expansion of bio-manufacturing facilities in Canada to increase fill-finish capacity for vaccines and therapies, including live and viral vector vaccines.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.